JP2013544880A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013544880A5 JP2013544880A5 JP2013542666A JP2013542666A JP2013544880A5 JP 2013544880 A5 JP2013544880 A5 JP 2013544880A5 JP 2013542666 A JP2013542666 A JP 2013542666A JP 2013542666 A JP2013542666 A JP 2013542666A JP 2013544880 A5 JP2013544880 A5 JP 2013544880A5
- Authority
- JP
- Japan
- Prior art keywords
- absent
- disease
- alkyl
- methyl
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 28
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 17
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 14
- 239000000460 chlorine Substances 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 229910052801 chlorine Inorganic materials 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- 125000001424 substituent group Chemical group 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 7
- 206010063837 Reperfusion injury Diseases 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000002947 alkylene group Chemical group 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 208000027866 inflammatory disease Diseases 0.000 claims 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 4
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 4
- 206010048554 Endothelial dysfunction Diseases 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 230000008694 endothelial dysfunction Effects 0.000 claims 4
- 230000036542 oxidative stress Effects 0.000 claims 4
- 238000002512 chemotherapy Methods 0.000 claims 3
- 208000026278 immune system disease Diseases 0.000 claims 3
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 3
- 230000004770 neurodegeneration Effects 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 238000001356 surgical procedure Methods 0.000 claims 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 2
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 238000001815 biotherapy Methods 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000002837 carbocyclic group Chemical group 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000002674 ointment Substances 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical class O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 claims 1
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 claims 1
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000025962 Crush injury Diseases 0.000 claims 1
- 208000002249 Diabetes Complications Diseases 0.000 claims 1
- 206010012655 Diabetic complications Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- 208000008069 Geographic Atrophy Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims 1
- 208000032571 Infant acute respiratory distress syndrome Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000004852 Lung Injury Diseases 0.000 claims 1
- 206010028116 Mucosal inflammation Diseases 0.000 claims 1
- 201000010927 Mucositis Diseases 0.000 claims 1
- 206010028851 Necrosis Diseases 0.000 claims 1
- 206010051606 Necrotising colitis Diseases 0.000 claims 1
- 206010028974 Neonatal respiratory distress syndrome Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 208000021063 Respiratory fume inhalation disease Diseases 0.000 claims 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 206010049771 Shock haemorrhagic Diseases 0.000 claims 1
- 206010040943 Skin Ulcer Diseases 0.000 claims 1
- 208000008475 Smoke Inhalation Injury Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010069363 Traumatic lung injury Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- MXZNUGFCDVAXLG-CHWSQXEVSA-N [(2S)-1-[(2R)-3-methyl-2-(pyridine-4-carbonylamino)butanoyl]pyrrolidin-2-yl]boronic acid Chemical compound CC(C)[C@@H](NC(=O)c1ccncc1)C(=O)N1CCC[C@@H]1B(O)O MXZNUGFCDVAXLG-CHWSQXEVSA-N 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 208000037883 airway inflammation Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 208000007474 aortic aneurysm Diseases 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 229920002988 biodegradable polymer Polymers 0.000 claims 1
- 239000004621 biodegradable polymer Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 230000002612 cardiopulmonary effect Effects 0.000 claims 1
- 238000013172 carotid endarterectomy Methods 0.000 claims 1
- 230000005796 circulatory shock Effects 0.000 claims 1
- 206010010121 compartment syndrome Diseases 0.000 claims 1
- 229940126208 compound 22 Drugs 0.000 claims 1
- 229940125878 compound 36 Drugs 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000010102 embolization Effects 0.000 claims 1
- 239000003995 emulsifying agent Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000002085 irritant Substances 0.000 claims 1
- 231100000021 irritant Toxicity 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 231100000515 lung injury Toxicity 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 230000017074 necrotic cell death Effects 0.000 claims 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 claims 1
- 201000002652 newborn respiratory distress syndrome Diseases 0.000 claims 1
- 239000000082 organ preservation Substances 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- -1 patch Substances 0.000 claims 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000011505 plaster Substances 0.000 claims 1
- 238000011471 prostatectomy Methods 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical group [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 claims 1
- 230000010410 reperfusion Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 231100000075 skin burn Toxicity 0.000 claims 1
- 231100000019 skin ulcer Toxicity 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 238000013151 thrombectomy Methods 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42138210P | 2010-12-09 | 2010-12-09 | |
| US61/421,382 | 2010-12-09 | ||
| PCT/IL2011/000931 WO2012077108A1 (en) | 2010-12-09 | 2011-12-08 | Multifunctional nitroxide derivatives and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013544880A JP2013544880A (ja) | 2013-12-19 |
| JP2013544880A5 true JP2013544880A5 (enExample) | 2015-01-15 |
| JP5853030B2 JP5853030B2 (ja) | 2016-02-09 |
Family
ID=45496220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013542666A Expired - Fee Related JP5853030B2 (ja) | 2010-12-09 | 2011-12-08 | 多機能ニトロキシド誘導体およびその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US9102659B2 (enExample) |
| EP (1) | EP2649048B1 (enExample) |
| JP (1) | JP5853030B2 (enExample) |
| CN (1) | CN103347856B (enExample) |
| AU (1) | AU2011340037B2 (enExample) |
| BR (1) | BR112013014190A2 (enExample) |
| CA (1) | CA2820763A1 (enExample) |
| DK (1) | DK2649048T3 (enExample) |
| ES (1) | ES2580104T3 (enExample) |
| HR (1) | HRP20160747T1 (enExample) |
| HU (1) | HUE029466T2 (enExample) |
| PL (1) | PL2649048T3 (enExample) |
| PT (1) | PT2649048T (enExample) |
| RS (1) | RS54889B1 (enExample) |
| RU (1) | RU2597265C2 (enExample) |
| SI (1) | SI2649048T1 (enExample) |
| WO (1) | WO2012077108A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014136059A2 (en) * | 2013-03-05 | 2014-09-12 | Radikal Therapeutics Inc. | Prodrugs of multifunctional nitroxide derivatives and uses thereof |
| JP6557977B2 (ja) * | 2015-01-15 | 2019-08-14 | Jnc株式会社 | 含窒素環化合物を含有する液晶組成物および液晶表示素子 |
| WO2017208129A1 (en) | 2016-05-31 | 2017-12-07 | Tisbury Pharmaceuticals, Inc. | Pharmaceutical composition and method for reducing intraocular pressure |
| CN111630048B (zh) * | 2018-03-19 | 2023-09-29 | 四川科伦博泰生物医药股份有限公司 | 脒类和胍类衍生物、其制备方法及其在医药上的应用 |
| WO2021044413A1 (en) * | 2019-09-03 | 2021-03-11 | Salzman Group Ltd. | Atp-regulated potassium channel openers comprising guanidine and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2A (en) * | 1826-12-15 | 1836-07-29 | John Goulding | Mode of manufacturing wool or other fibrous materials |
| GB1489879A (en) * | 1974-12-20 | 1977-10-26 | Leo Pharm Prod Ltd | N'-cyano-n'-3-pyridylguanidines |
| US5011837A (en) * | 1988-08-09 | 1991-04-30 | E. R. Squibb & Sons, Inc. | Aryl cyanoguanidines: potassium channel activators and method of making same |
| US5132311A (en) * | 1990-06-27 | 1992-07-21 | G. D. Searle & Co. | Cyanoquanidine type III antiarrhythmic agents and use |
| US5374643A (en) * | 1992-09-11 | 1994-12-20 | E. R. Squibb & Sons, Inc. | Aryl urea (thiourea) and cyanoguanidine derivatives |
| ES2377126T3 (es) * | 1994-12-12 | 2012-03-22 | Omeros Corporation | Solución de irrigación y utilización de la misma para la inhibición perioperatoria del dolor, la inflamación y/o los espasmos en una estructura vascular |
| JP2002536411A (ja) * | 1999-02-09 | 2002-10-29 | ブリストル−マイヤーズ スクイブ カンパニー | Ｘａ因子のラクタム系阻害剤および方法 |
| EP1397355B1 (en) * | 2001-05-24 | 2009-09-09 | Leo Pharma A/S | Pyridyl cyanoguanidine compounds |
| AUPS312602A0 (en) * | 2002-06-21 | 2002-07-18 | James Cook University | Organ arrest, protection, preservation and recovery |
| EP1603556A2 (en) * | 2003-03-06 | 2005-12-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Sod mimic multifunctional compounds for treating inflammatory bowel disease |
| US20060025446A1 (en) * | 2004-07-27 | 2006-02-02 | Jeffrey Sterling | Propargyl nitroxides and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders |
| CN1854135B (zh) * | 2005-04-18 | 2013-06-12 | 李伟章 | 由氰基胍连接组成的杂环化合物及其医药应用 |
| US20070275944A1 (en) * | 2006-04-05 | 2007-11-29 | The Board Of Trustees Operating Michigan State University | Antioxidants and methods of their use |
| US7683043B2 (en) * | 2006-06-06 | 2010-03-23 | Xenoport, Inc. | Creatine phosphate analog prodrugs, compositions and uses thereof |
| US20090253745A1 (en) * | 2007-11-28 | 2009-10-08 | Sirion Therapeutics, Inc. | Modulators of ocular oxidative stress |
-
2011
- 2011-12-08 US US13/992,396 patent/US9102659B2/en not_active Expired - Fee Related
- 2011-12-08 PT PT118089457T patent/PT2649048T/pt unknown
- 2011-12-08 RU RU2013126219/04A patent/RU2597265C2/ru not_active IP Right Cessation
- 2011-12-08 AU AU2011340037A patent/AU2011340037B2/en not_active Ceased
- 2011-12-08 WO PCT/IL2011/000931 patent/WO2012077108A1/en not_active Ceased
- 2011-12-08 ES ES11808945.7T patent/ES2580104T3/es active Active
- 2011-12-08 DK DK11808945.7T patent/DK2649048T3/en active
- 2011-12-08 BR BR112013014190A patent/BR112013014190A2/pt active Search and Examination
- 2011-12-08 PL PL11808945.7T patent/PL2649048T3/pl unknown
- 2011-12-08 CN CN201180067011.6A patent/CN103347856B/zh not_active Expired - Fee Related
- 2011-12-08 HR HRP20160747TT patent/HRP20160747T1/hr unknown
- 2011-12-08 RS RS20160494A patent/RS54889B1/sr unknown
- 2011-12-08 HU HUE11808945A patent/HUE029466T2/en unknown
- 2011-12-08 CA CA2820763A patent/CA2820763A1/en not_active Abandoned
- 2011-12-08 EP EP11808945.7A patent/EP2649048B1/en active Active
- 2011-12-08 SI SI201130873A patent/SI2649048T1/sl unknown
- 2011-12-08 JP JP2013542666A patent/JP5853030B2/ja not_active Expired - Fee Related
-
2015
- 2015-07-31 US US14/815,783 patent/US9522903B2/en not_active Expired - Fee Related
-
2016
- 2016-12-19 US US15/384,094 patent/US20170107198A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019518766A5 (enExample) | ||
| JP2019510787A5 (enExample) | ||
| JP2019529490A5 (enExample) | ||
| RU2017121906A (ru) | Конъюгаты цистеамина и жирной кислоты и их применение в качестве активаторов аутофагии | |
| JP2020502047A5 (enExample) | ||
| JP2018536648A5 (enExample) | ||
| JP2014503525A5 (enExample) | ||
| JP2011520815A5 (enExample) | ||
| JP2019094345A5 (enExample) | ||
| JP2013544880A5 (enExample) | ||
| RU2020112502A (ru) | Циклические динуклеотиды в качестве стимулятора модуляторов генов интерферона | |
| JP2012500260A5 (enExample) | ||
| JP2016121196A5 (enExample) | ||
| JP2009524691A5 (enExample) | ||
| JP2014511891A5 (enExample) | ||
| JP2012236838A5 (enExample) | ||
| JP2010540525A5 (enExample) | ||
| JP2014037426A5 (enExample) | ||
| JP2014511892A5 (enExample) | ||
| JP2009527501A5 (enExample) | ||
| RU2003105805A (ru) | Производные 4-фенилпиридина в качестве антагонистов рецепторов нейрокинина-1 | |
| RU2013154412A (ru) | Аминопиримидины в качестве ингибиторов syc | |
| JP2005504789A5 (enExample) | ||
| RU2014122033A (ru) | Соединения с нематоцидной активностью | |
| JP2013532652A5 (enExample) |